PT1019048E - Uso de um antagonista do receptor da angiotensina ii para a preparacao de farmacos para aumentar a taxa de sobrevivencia de pacientes sujeitos a transplante renal - Google Patents

Uso de um antagonista do receptor da angiotensina ii para a preparacao de farmacos para aumentar a taxa de sobrevivencia de pacientes sujeitos a transplante renal

Info

Publication number
PT1019048E
PT1019048E PT98946713T PT98946713T PT1019048E PT 1019048 E PT1019048 E PT 1019048E PT 98946713 T PT98946713 T PT 98946713T PT 98946713 T PT98946713 T PT 98946713T PT 1019048 E PT1019048 E PT 1019048E
Authority
PT
Portugal
Prior art keywords
drugs
preparation
receptor antagonist
angiotensin
enhance
Prior art date
Application number
PT98946713T
Other languages
English (en)
Inventor
Giuseppe Remuzzi
Original Assignee
Merck Sharp Dohme Italia S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp Dohme Italia S P A filed Critical Merck Sharp Dohme Italia S P A
Publication of PT1019048E publication Critical patent/PT1019048E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT98946713T 1997-09-30 1998-09-30 Uso de um antagonista do receptor da angiotensina ii para a preparacao de farmacos para aumentar a taxa de sobrevivencia de pacientes sujeitos a transplante renal PT1019048E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97RM000586A IT1295405B1 (it) 1997-09-30 1997-09-30 Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di

Publications (1)

Publication Number Publication Date
PT1019048E true PT1019048E (pt) 2004-05-31

Family

ID=11405271

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98946713T PT1019048E (pt) 1997-09-30 1998-09-30 Uso de um antagonista do receptor da angiotensina ii para a preparacao de farmacos para aumentar a taxa de sobrevivencia de pacientes sujeitos a transplante renal

Country Status (12)

Country Link
US (1) US6576652B2 (pt)
EP (1) EP1019048B1 (pt)
JP (1) JP2001517698A (pt)
AT (1) ATE258051T1 (pt)
AU (1) AU754852B2 (pt)
CA (1) CA2303217C (pt)
DE (1) DE69821252T2 (pt)
DK (1) DK1019048T3 (pt)
ES (1) ES2213296T3 (pt)
IT (1) IT1295405B1 (pt)
PT (1) PT1019048E (pt)
WO (1) WO1999016437A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
BR0102252B1 (pt) 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
ATE321039T1 (de) 2002-04-29 2006-04-15 Teva Pharma Verfahren zur herstellung von losartan und losartan-kaliumsalz
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
WO2005110386A2 (en) * 2004-04-13 2005-11-24 Wisconsin Alumni Research Foundation Method of decreasing inflammation in kidney transplantation using angiotensin receptor blockers
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
EP2426127B1 (en) * 2009-04-28 2019-09-04 Daiichi Sankyo Company, Limited Novel solvate crystals
HUE037736T2 (hu) 2012-11-14 2018-09-28 Teijin Pharma Ltd Piridin származékok
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
KR20200136974A (ko) * 2018-03-29 2020-12-08 브루노 라이케르트 심장, 신장, 폐 또는 간의 동소성 및 이소성 이종 이식 후 생존을 연장하기 위한 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH528514A (de) 1969-05-22 1972-09-30 Bayer Ag Verfahren zur Herstellung von Acylimidazolen
JPS54148788A (en) 1978-05-15 1979-11-21 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative and its preparation
JPS55313A (en) 1978-06-13 1980-01-05 Kissei Pharmaceut Co Ltd Imidazole derivative
DK531479A (da) 1979-01-19 1980-07-20 Pfizer Fremgangsmaade til fremstilling af imidazolderivater og salte deraf
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
DE3106150A1 (de) 1981-02-13 1982-09-16 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verfahren zur herstellung von imidazolessigsaeurederivaten"
JPS58157768A (ja) 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
PT78388B (en) 1983-04-12 1986-09-15 Smithkline Beckman Corp Dopamine-beta-hydroxylase inhibitors
FI833794A0 (fi) 1983-10-18 1983-10-18 Farmos Oy Substituerade 2-merkapto-imidazoler
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
EP0505098A1 (en) * 1991-03-19 1992-09-23 Merck & Co. Inc. Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
WO1993010106A1 (en) 1991-11-18 1993-05-27 E.I. Du Pont De Nemours And Company Tetrazolylphenylboronic acid intermediates for the synthesis of aii receptor antagonists
US5130439A (en) 1991-11-18 1992-07-14 Lo Young S Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US5310929A (en) * 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
US5395844A (en) * 1993-06-10 1995-03-07 The Du Pont Merck Pharmaceutical Company Imidazole 5-position substituted angiotensin II antagonists
EP0853477B1 (en) * 1995-10-06 2002-10-09 Novartis AG At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
EP0868179A4 (en) * 1995-12-12 2002-01-30 Merck & Co Inc NEW USE OF LOSARTAN

Also Published As

Publication number Publication date
US20020115702A1 (en) 2002-08-22
AU754852B2 (en) 2002-11-28
DE69821252T2 (de) 2004-11-18
IT1295405B1 (it) 1999-05-12
WO1999016437A1 (en) 1999-04-08
DE69821252D1 (de) 2004-02-26
JP2001517698A (ja) 2001-10-09
AU9366698A (en) 1999-04-23
US6576652B2 (en) 2003-06-10
CA2303217C (en) 2005-08-09
ATE258051T1 (de) 2004-02-15
ES2213296T3 (es) 2004-08-16
DK1019048T3 (da) 2004-05-03
EP1019048A1 (en) 2000-07-19
ITRM970586A1 (it) 1999-03-30
CA2303217A1 (en) 1999-04-08
EP1019048B1 (en) 2004-01-21

Similar Documents

Publication Publication Date Title
CL2004000860A1 (es) Compuesto biciclico de pirazol o imidazol de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de un medicam
PT1019048E (pt) Uso de um antagonista do receptor da angiotensina ii para a preparacao de farmacos para aumentar a taxa de sobrevivencia de pacientes sujeitos a transplante renal
CA2085584A1 (en) Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
EP1327631A3 (en) Fused heterocyclic compounds, their production and use as angiotensin II antagonists
PE99999A1 (es) 4,5-diarilimidazoles 2-sustituidos
CA2643005A1 (en) Imidazole-5-carboxylic acid derivatives,the preparation method therefor and the uses thereof
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
KR960704884A (ko) 항종양제 또는 항바이러스제로서의 디스타마이신 A 동족체 (Distamycin A analogues as antitumour or antiviral agents)
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
DE60130256D1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
SV2008002969A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ATE197951T1 (de) Neue imidazol derivate, ihre herstellung und therapeutische verwendung
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626153A (en) Heterocyclic derivatives and their use as therapeutic agents
MXPA04000173A (es) Compuestos basados en peptidos.
FI915099A (fi) Tienoimidazolderivat, deras framstaellning och anvaendning aendning.
PE20061195A1 (es) Derivado de bencimidazol como antagonista de angiotensina ii
WO2007125398A3 (en) : sulfonamide compounds as antagonists of the n-type calcium channel
CA2420055A1 (en) Fibrinogen-lowering agent
CA2539985A1 (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
UA83868C2 (ru) Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1
RS20060072A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
TR200001412T2 (tr) Çok miktarda ilaç içeren, derhal ve modifike bir salgılama sağlayan oral doz formülasyonları ve bunların imal edilmesi için proses.
US20020058686A1 (en) Medicament